[PMID]: | 28576832 |
[Au] Autor: | Cao J; Singh SP; McClung JA; Joseph G; Vanella L; Barbagallo I; Jiang H; Falck JR; Arad M; Shapiro JI; Abraham NG |
[Ad] Endereço: | Departments of Medicine and Pharmacology, New York Medical College, Valhalla, New York. |
[Ti] Título: | EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice. |
[So] Source: | Am J Physiol Heart Circ Physiol;313(2):H368-H380, 2017 Aug 01. |
[Is] ISSN: | 1522-1539 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | We have previously reported that epoxyeicosatrienoic acid (EET) has multiple beneficial effects on vascular function; in addition to its antiapoptotic action, it increases insulin sensitivity and inhibits inflammation. To uncover the signaling mechanisms by which EET reduces cardiomyopathy, we hypothesized that EET infusion might ameliorate obesity-induced cardiomyopathy by improving heme oxygenase (HO)-1, Wnt1, thermogenic gene levels, and mitochondrial integrity in cardiac tissues and improved pericardial fat phenotype. EET reduced levels of fasting blood glucose and proinflammatory adipokines, including nephroblastoma overexpressed (NOV) signaling, while increasing echocardiographic fractional shortening and O consumption. Of interest, we also noted a marked improvement in mitochondrial integrity, thermogenic genes, and Wnt 1 and HO-1 signaling mechanisms. Knockout of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) in EET-treated mice resulted in a reversal of these beneficial effects including a decrease in myocardial Wnt1 and HO-1 expression and an increase in NOV. To further elucidate the effects of EET on pericardial adipose tissues, we observed EET treatment increases in adiponectin, PGC-1α, phospho-AMP-activated protein kinase, insulin receptor phosphorylation, and thermogenic genes, resulting in a "browning" pericardial adipose phenotype under high-fat diets. Collectively, these experiments demonstrate that an EET agonist increased Wnt1 and HO-1 signaling while decreasing NOV pathways and the progression of cardiomyopathy. Furthermore, this report presents a portal into potential therapeutic approaches for the treatment of heart failure and metabolic syndrome. The mechanism by which EET acts on obesity-induced cardiomyopathy is unknown. Here, we describe a previously unrecognized function of EET infusion that inhibits nephroblastoma overexpressed (NOV) levels and activates Wnt1, hence identifying NOV inhibition and enhanced Wnt1 expression as novel pharmacological targets for the prevention and treatment of cardiomyopathy and heart failure.Listen to this article's corresponding podcast at http://ajpheart.physiology.org/content/early/2017/05/31/ajpheart.00093.2017. |
[Mh] Termos MeSH primário: |
Tecido Adiposo/efeitos dos fármacos Cardiomiopatias/prevenção & controle Eicosanoides/farmacologia Heme Oxigenase-1/metabolismo Proteínas de Membrana/metabolismo Miócitos Cardíacos/efeitos dos fármacos Proteína Sobre-Expressa em Nefroblastoma/metabolismo Obesidade/tratamento farmacológico Via de Sinalização Wnt/efeitos dos fármacos Proteína Wnt1/metabolismo
|
[Mh] Termos MeSH secundário: |
Células 3T3-L1 Adipocinas/metabolismo Tecido Adiposo/enzimologia Tecido Adiposo/fisiopatologia Animais Biomarcadores/sangue Glicemia/efeitos dos fármacos Glicemia/metabolismo Pressão Sanguínea Cardiomiopatias/enzimologia Cardiomiopatias/etiologia Cardiomiopatias/fisiopatologia Modelos Animais de Doenças Mediadores da Inflamação/metabolismo Camundongos Camundongos Knockout Mitocôndrias Cardíacas/efeitos dos fármacos Mitocôndrias Cardíacas/enzimologia Miócitos Cardíacos/enzimologia Obesidade/complicações Obesidade/enzimologia Obesidade/fisiopatologia Consumo de Oxigênio Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/deficiência Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/genética Remodelação Ventricular Ganho de Peso/efeitos dos fármacos Proteínas Wnt/metabolismo beta Catenina
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE; WEBCASTS |
[Nm] Nome de substância:
| 0 (Adipokines); 0 (Biomarkers); 0 (Blood Glucose); 0 (CTNNB1 protein, mouse); 0 (Eicosanoids); 0 (Inflammation Mediators); 0 (Membrane Proteins); 0 (Nephroblastoma Overexpressed Protein); 0 (Nov protein, mouse); 0 (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha); 0 (Ppargc1a protein, mouse); 0 (Wnt Proteins); 0 (Wnt1 Protein); 0 (Wnt1 protein, mouse); 0 (Wnt5b protein, mouse); 0 (beta Catenin); EC 1.14.14.18 (Heme Oxygenase-1); EC 1.14.14.18 (Hmox1 protein, mouse) |
[Em] Mês de entrada: | 1708 |
[Cu] Atualização por classe: | 170907 |
[Lr] Data última revisão:
| 170907 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170604 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1152/ajpheart.00093.2017 |
|
|